NCT06309485 - Phase 2 Study of WGI-0301 for Advanced HCC | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 31, 2024

Primary Completion Date

August 31, 2026

Study Completion Date

December 31, 2026

Conditions

Advanced Hepatocellular Carcinoma (HCC)

Interventions

DRUG

WGI-0301 at MTD/RP2D dose IV infusion, QW

WGI-0301 is a lipid nanoparticle preparation of Archexin®, a 20-mer oligonucleotide that is complementary to Akt-1 mRNA, formulated for the treatment of advanced HCC.

DRUG

WGI-0301 at MTD/RP2D -1 dose IV infusion, QW

WGI-0301 is a lipid nanoparticle preparation of Archexin®, a 20-mer oligonucleotide that is complementary to Akt-1 mRNA, formulated for the treatment of advanced HCC.

DRUG

Sorafenib 400 mg PO, BID continuously

Sorafenib is an oral multi-kinase inhibitor used for the treatment of hepatocellular carcinoma.

DRUG

Sorafenib 400 mg PO, BID

Sorafenib is an oral multi-kinase inhibitor used for the treatment of hepatocellular carcinoma.

All Listed Sponsors

lead

Zhejiang Haichang Biotech Co., Ltd.

INDUSTRY